Core Viewpoint - The company held its third meeting of the ninth supervisory board, where several key resolutions were passed, including amendments to the company's articles of association and adjustments to the employee stock ownership plan [1][2]. Group 1: Resolutions Passed - The supervisory board approved the proposal to amend the company's articles of association with a vote of 3 in favor, 0 against, and 0 abstentions [1]. - The proposal regarding adjustments to the fourth employee stock ownership plan was discussed but could not be resolved due to insufficient non-related supervisors present for a quorum [2]. - The supervisory board approved the proposal to extend the fundraising project with a unanimous vote of 3 in favor, 0 against, and 0 abstentions [2]. Group 2: Meeting Details - The meeting was convened on June 18, 2025, and was chaired by Mr. Zhang Jisong, the chairman of the supervisory board [1]. - The meeting complied with the requirements of the Company Law of the People's Republic of China and the company's articles of association [1].

Core Viewpoint - The company, Shandong Kehui Power Automation Co., Ltd., has announced a delay in some of its fundraising projects, which is a prudent decision based on the actual progress of the projects and does not alter the investment content or total amount [2][6]. Fundraising Basic Situation - The company successfully issued 26.17 million shares at a price of RMB 19,282,662.77, resulting in a net fundraising amount of RMB 45,623,360.81 as of May 31, 2025 [2][3]. Fund Usage Status - The fundraising projects include the "Smart Grid Fault Monitoring and Automation Product Upgrade Project" and the "Modern Electrical Automation Technology Research Institute Construction Project," with specific funding amounts and progress reported [4][5]. Delay of Fundraising Projects - The company plans to postpone the expected completion dates for the projects to December 2025 due to the need for synchronization in project implementation and ongoing construction progress [5][6]. Measures to Ensure Completion - The company will adhere to relevant regulations and strengthen supervision over the use of fundraising, ensuring that the projects are completed on time despite the delays [6][7]. Impact of Delay - The delay is not expected to have a significant adverse effect on the company's normal operations or long-term development plans, as it does not change the investment direction or harm shareholder interests [6][8]. Review Procedures - Both the board of directors and the supervisory board have approved the delay, confirming that the decision complies with regulatory requirements and does not harm shareholder interests [6][7].

Meeting Overview - The third meeting of the Supervisory Board of Hangzhou Anjisi Medical Technology Co., Ltd. was held on June 17, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Resolutions Passed - The Supervisory Board approved the proposal to grant restricted stock to three eligible incentive objects under the 2025 Restricted Stock Incentive Plan at a price of 46.16 yuan per share, totaling 16,089 shares [1][2]. - The Supervisory Board approved the proposal to postpone certain fundraising investment projects, stating that the decision was made based on the actual construction situation and did not harm shareholders' interests [2]. - The Supervisory Board approved the use of self-owned foreign exchange funds to pay for the required funds for fundraising projects, with a plan to replace the amount with raised funds, ensuring compliance with relevant regulations and improving fund utilization efficiency [3].

Group 1 - The fifth meeting of the supervisory board of Ningbo Top Group Co., Ltd. was held on June 17, 2025, with all three supervisors present, complying with relevant laws and regulations [1][2] - The supervisory board approved the proposal to change the use of part of the raised funds, stating that the adjustment aligns with the company's strategic planning and actual development, enhancing the efficiency of fund utilization [1][2] - The supervisory board also approved the proposal for the postponement of some fundraising projects, emphasizing that this decision is also aimed at rational fund utilization and does not harm the interests of the company and its shareholders [2]

Core Viewpoint - The actual controller of Shanghai Yanpu, Zhou Jianqing, plans to reduce his stake in the company amid declining revenue, indicating personal financial needs and raising concerns about the company's future performance [1][2]. Group 1: Shareholding and Reduction - Zhou Jianqing intends to reduce his holdings by up to 633 million shares, which represents approximately 2.998% of the company's total shares [2][3]. - As of the announcement date, Zhou holds 67.73 million shares, accounting for 32.08% of the total shares, all of which are unrestricted circulating shares [2][3]. Group 2: Financial Performance - In Q1 2025, the company reported revenue of 433 million yuan, a year-on-year decrease of 23.92%, while net profit was 32.84 million yuan, an increase of 2.49% [1][7]. - For the year 2024, the company achieved revenue of 2.276 billion yuan, a year-on-year increase of 49.90%, and net profit of 137 million yuan, up 50.31% [7]. - The company's net profit has shown significant fluctuations from 2021 to 2023, with figures of 70.48 million yuan, 45.74 million yuan, and 91.18 million yuan, reflecting year-on-year changes of -13.24%, -35.10%, and 99.32% respectively [6][7]. Group 3: Project Delays and Funding - The company has faced delays in its fundraising projects, specifically the "Jingmen Yanpu Automotive Parts Co., Ltd. Great Wall Motor Seat Frame Project," which has been postponed twice, now expected to reach operational status by June 2025 [4][5][6]. - The total amount raised through convertible bonds was 384 million yuan, with 71% of the funds utilized as of the end of 2024 [4].

Group 1 - The company announced a delay in the completion dates for two fundraising investment projects, moving the expected operational status from June 2025 to June 2026 [1] - The projects affected are the "Pharmaceutical Liquid Preparation System Production Center Construction Project" and the "Pharmaceutical R&D Service Platform Upgrade and Expansion Project" [1] - The delay does not change the investment content, total amount, or implementing entity, and is not expected to have a substantial impact on project implementation or the company's normal operations [1] Group 2 - As of May 31, 2025, the company has cumulatively invested 164 million yuan in the fundraising projects, with a remaining balance of 109 million yuan in the fundraising account [1]

Core Viewpoint - The company announced the postponement of the completion dates for several fundraising investment projects due to various external factors, ensuring that the use of raised funds remains compliant and effective [1] Group 1: Project Delays - The completion date for the "Integrated Natural Plant Extraction Project (Phase I)" has been postponed to June 30, 2027 [1] - The "Nutritional Medicinal Comprehensive Extraction Project (Phase I)" is now expected to be completed by April 30, 2027 [1] - The "Zambia Land Development and Supporting Infrastructure Construction Project" will now reach its intended operational status by December 31, 2026 [1] Group 2: Reasons for Delay - The delays are attributed to changes in the global economic environment, slow market expansion, and ongoing optimization of production processes [1] Group 3: Impact on Operations - The company stated that these delays will not have a significant adverse impact on its normal operations [1]

Group 1 - The company held its third board meeting and supervisory board meeting on June 17, 2025, where it approved the use of its own foreign exchange funds to pay for the investment project and to replace it with raised funds [2][7][9] - The company successfully raised a total of RMB 182,032.60 million by issuing 14,470,000 shares at a price of RMB 125.80 per share, with a net amount of RMB 165,101.28 million after deducting issuance costs [2][43][44] - The company plans to use the raised funds for the "Anjisi Thailand Production Base Project" and has established a three-party supervision agreement for the management of the raised funds [3][4][43] Group 2 - The company will use its own foreign exchange funds to pay for part of the investment project during its implementation and will replace these with raised funds later, which is aimed at improving operational efficiency and reducing financial costs [5][6][7] - The company has approved the extension of the "Minimally Invasive Medical Device R&D Center Project" to December 31, 2026, due to the actual construction progress and strategic planning [4][54][55] - The supervisory board and the sponsor have confirmed that the use of foreign exchange funds and the extension of the investment project will not affect the normal implementation of the investment projects and will not harm the interests of shareholders [8][9][57] Group 3 - The company has established a detailed operational process for the use of its own foreign exchange funds and the subsequent replacement with raised funds, ensuring compliance with relevant regulations [6][8][9] - The company emphasizes the necessity and feasibility of the investment projects, highlighting the importance of technological innovation and talent attraction in maintaining competitive advantages in the medical device industry [46][50][51] - The company believes that the investment projects align with its strategic planning and will continue to monitor conditions for timely adjustments [52][53]

Group 1 - The board of directors of Luoyang Jianlong Micro-Nano New Materials Co., Ltd. held its 11th meeting of the 4th session on June 17, 2025, with all 8 directors present, ensuring compliance with legal and regulatory requirements [1] - The board decided not to lower the conversion price of "Jianlong Convertible Bonds" due to the long remaining term and recent market adjustments, affirming confidence in the company's future development [1][2] - The board approved a postponement of the "Adsorption Material Industrial Park Expansion Project (Phase II)" completion date from June 2025 to December 2026, without altering the project's implementation or funding [2] Group 2 - The board reviewed and approved amendments to certain internal management systems to align with the latest legal requirements, particularly following the cancellation of the supervisory board structure [2][3] - All resolutions passed unanimously with 8 votes in favor and no opposition or abstentions [2][3][4]

Core Viewpoint - The company, Guangdong Jushi Chemical Co., Ltd., is undergoing a delay in some of its fundraising projects, which has been reviewed and approved by its board of directors, ensuring compliance with relevant regulations and maintaining the integrity of its investment plans [1][5]. Fundraising Overview - The company raised a total of RMB 855.1667 million through the issuance of 23.333334 million shares at a price of RMB 36.65 per share, with all funds received by January 19, 2021 [1][2]. - The raised funds are stored in a special account approved by the board, with a regulatory agreement in place with the sponsoring institution and the bank [2]. Investment Project Status - As of March 31, 2025, the total planned investment for the projects is RMB 1.2005951 billion, with cumulative investment amounting to RMB 552.4919 million, achieving a progress rate of 99.39% [3]. - The company has decided to conclude certain projects and reallocate surplus funds to enhance liquidity [3]. Delay Details - The delay in the "Chizhou Halogen-Free Flame Retardant Expansion Project" and "Anqing Polystyrene Production Project" is attributed to various factors, including climate conditions, construction capabilities, equipment debugging, and administrative approvals [4]. - The company has taken a cautious approach to control the investment pace of the "Anqing Polystyrene Production Project" due to external economic conditions and internal strategic adjustments [4]. Measures for Completion - The company plans to closely monitor market changes, expedite administrative approvals, optimize resource allocation, and enhance project supervision to ensure timely completion of the delayed projects [4]. Impact of Delay - The delay is a prudent decision based on actual project conditions and does not alter the investment content, total investment, or intended use of funds, thus not significantly impacting the company's normal operations or shareholder interests [4][5]. - The company will continue to adhere to regulatory requirements and strengthen both internal and external oversight of fund usage [5].